Complete Resolution of a Large, Locally-advanced Cutaneous Squamous Cell Carcinoma with the Immune-modulating PD-1 Inhibitor Pembrolizumab

Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Cristancho, Cagney, Riano, Ivy, Guareras-Paredes, Daniel, Park, Robin, Seetharaman, Kala
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290116/
https://www.ncbi.nlm.nih.gov/pubmed/32542127
http://dx.doi.org/10.7759/cureus.8072
Descripción
Sumario:Locally advanced cutaneous squamous cell carcinoma (cSCC) represents a challenge in treatment. Only very recently (February 2020) have guidelines been released regarding the management of unresectable, locally advanced cSCC. With the introduction of check point inhibitors during the last decade, anti-PD-1 antibodies represent a novel immunotherapeutic strategy in cancer. We present a case of an advanced cSCC not amenable to surgical resection, who experienced dramatic improvement following treatment with the programmed cell death protein 1 receptor (PD-1) inhibitor pembrolizumab as an immunotherapeutic strategy.

Ejemplares similares